We present the case of a 61-year-old patient infected with chronic hepatitis C virus (HCV) genotype 3, F1 fibrosis and history of short bowel syndrome, dependent on total parenteral nutrition (TPN) who was referred to the clinical pharmacist for HCV treatment. Following 12 weeks of treatment with crushed, orally administered sofosbuvir/velpatasvir (SOF/VEL) the patient was unable to achieve sustained virologic response (SVR12), suggesting that this therapy may be ineffective in patients with short bowel syndrome.
MartinMTPatelSChacraW. Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case report of an adult with short bowel syndrome. J Hepatol. 2023;79(5):E185-E187.
6.
MurayamaATajiriKKaneganeCMurakamiJHayashiYYasudaI. Successful treatment with crushed sofosbuvir/velpatasvir of a patient with decompensated cirrhosis C and thrombocytopenia. Case Rep Gastroenterol. 2021;15(2):729-735.
7.
MogulATeixeiraEMcAuliffeLPromratKZulloAR. Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia. Am J Health Syst Pharm. 2020;77(6):417-418.
8.
van SeyenMSamsonADCullenL, et al.Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. Int J Antimicrob Agents. 2020;55(6):105934.
9.
JoshiSCohenMKatzR, et al.A case series of safety and efficacy of crushed sofosbuvir/velpatasvir in hepatitis C infected patients. American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience. November 12-15, 2021. https://www.natap.org/2021/AASLD/AASLD_12.htm
MorelloJRodriguez-NovoaSJimenez-NacherISorianoV. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008;62(6):1174-1180.
16.
VionnetJSaouliA-CPascualM, et al.Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease. J Hepatol. 2016;65(5):1063-1065.
